镥-177标记PSMA-617联合帕博利珠单抗治疗转移性去势抵抗性前列腺癌:PRINCE单臂1b/2期研究
PRINCE研究为多中心单臂1b/2期试验,评估多周期[177Lu]Lu-PSMA-617联合帕博利珠单抗治疗mCRPC的安全性和50%PSA缓解率。37例患者中76%(95%CI 59-88)达到PSA下降≥50%,常见不良事件为1-2级,3级免疫相关不良事件发生率为30%,无4级不良事件或治疗相关死亡。联合方案显示出鼓舞人心的活性且毒性可控。
要点
- 多周期[177Lu]Lu-PSMA-617联合帕博利珠单抗在mCRPC中显示76%的PSA50缓解率。
- 常见不良事件为1-2级,3级免疫相关不良事件发生率为30%。
- 无4级不良事件或治疗相关死亡,毒性总体可控。
核心结论
- 多周期[177Lu]Lu-PSMA-617联合帕博利珠单抗显示出鼓舞人心的抗肿瘤活性,毒性可控且与单药已知安全性一致。
- 该联合方案可能为部分患者提供持久的临床获益。
研究设计与样本
- PRINCE为多中心、单臂、1b/2期试验,纳入37例mCRPC患者。
- 患者接受最多6周期[177Lu]Lu-PSMA-617(每6周静脉给药)联合帕博利珠单抗200 mg(每3周静脉给药,最长24个月)。
- 共同主要终点为安全性和50%PSA缓解率,所有接受治疗者均纳入分析。
主要发现
- 37例患者中28例(76%,95%CI 59-88)达到PSA较基线下降≥50%。
- 3级不良事件包括贫血1例(3%)和免疫相关不良事件11例(30%),后者包括乏力、结肠炎、血清淀粉酶升高各2例(5%)及胰腺炎、肺炎、1型糖尿病、肾炎、重症肌无力、黏膜天疱疮各1例(3%)。
- 无4级不良事件或治疗相关死亡。
关键数值与推荐
- 纳入标准:年龄≥18岁、mCRPC、ECOG体能状态0-1、既往接受过雄激素受体通路抑制剂治疗(允许既往多西他赛)、高PSMA表达。
- 50%PSA缓解率:28/37(76%,95%CI 59-88)。
- 3级免疫相关不良事件发生率:11/37(30%)。
临床怎么用
- 对于高PSMA表达、体能状态良好的mCRPC患者,可考虑[177Lu]Lu-PSMA-617联合帕博利珠单抗治疗。
- 治疗期间需监测免疫相关不良事件,尤其是结肠炎、内分泌毒性及神经肌肉毒性。
局限性
- 单臂设计,无对照组,样本量较小(37例),结果需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-617 improves overall survival and progression-free survival in metastatic castration resistant prostate cancer (mCRPC), whereas immune checkpoint inhibitors (ICIs) have limited activity. Preclinical evidence suggests radioligand therapy might induce immunogenic cell death that can be enhanced with ICIs. This study evaluates the activity and adverse event profile associated with multiple doses of [177Lu]Lu-PSMA-617 with pembrolizumab. METHODS: PRINCE was a multicentre, single-arm, phase 1b/2 trial of [177Lu]Lu-PSMA-617 and pembrolizumab. Eligible participants were aged 18 years or older, had mCRPC, an Eastern Cooperative Oncology Group performance status of 0-1, previous androgen receptor pathway inhibitor therapy with previous docetaxel allowed, and high PSMA expression. Participants received up to six cycles of [177Lu]Lu-PSMA-617 intravenously every 6 weeks with 200 mg of pembrolizumab intravenously every 3 weeks for up to 24 months. Co-primary endpoints were safety and 50% prostate-specific antigen (PSA) response rate. All participants who received treatment were included in the analysis. The trial is registered with ClinicalTrials.gov, NCT03658447, and has been completed. FINDINGS: Between Aug 22, 2019 and Dec 16, 2020, 37 participants (median age 72 years, IQR 67-76; 27 [73%] docetaxel pretreated) received a median of six cycles (IQR 4-6) of [177Lu]Lu-PSMA-617 and a median of 12 cycles (IQR 6-24) of pembrolizumab. Median follow up was 30 months (IQR 28-31). A decline in PSA of 50% or greater from baseline was observed in 28 (76%, 95% CI 59-88) of the 37 participants. Common treatment-related adverse events were grade 1-2. Grade 3 adverse events included anaemia in one (3%) participant and immune-related adverse events in 11 (30%) participants, including two cases each of fatigue (5%), colitis (5%), and increased serum amylase (5%), and one case (3%) each of pancreatitis, pneumonitis, type 1 diabetes, nephritis, myasthenia gravis, and mucosal pemphigus attributable to pembrolizumab. One participant had co-occurring myasthenia gravis and colitis. There were no grade 4 adverse events or treatment-related deaths. INTERPRETATION: Multicycle [177Lu]Lu-PSMA-617 and pembrolizumab showed encouraging activity with manageable toxicity that was consistent with [177Lu]Lu-PSMA-617 or pembrolizumab, and the combination might provide durable clinical benefit in a subset of patients. FUNDING: Victorian Cancer Agency, Merck Sharp & Dohme, and Novartis.
引用
- Sandhu S, Joshua AM, Emmett L, et al. [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study. Lancet Oncol. 2026. PMID: 41926961. doi:10.1016/S1470-2045(26)00017-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。